FFO
VKTX icon

Fortitude Family Office’s Viking Therapeutics VKTX Stock Holding History

Fortitude Family Office’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$780 Hold
20
– – ﹤0.01% 1839
2026
Q1 		$651 Hold
20
– – ﹤0.01% 1632
2025
Q4 		$704 Hold
20
– – ﹤0.01% 1590
2025
Q3 		$526 Hold
20
– – ﹤0.01% 1789
2025
Q2 		$530 Buy
+20
New +$526 ﹤0.01% 1778

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Fortitude Family Office's VKTX Position: Q2 2026 in Review

Fortitude Family Office held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 20 shares worth $780. The position accounts for ﹤0.01% of the portfolio, ranked #1839.

Fortitude Family Office first reported a position in VKTX in Q2 2025 and has held it in 5 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Fortitude Family Office held 20 shares of Viking Therapeutics worth $780 as of Q2 2026.
  • Fortitude Family Office left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1839 holding.
  • Fortitude Family Office first reported a position in Viking Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.